Positron Corporation Announces Attrius PET System Sale

Positron Corp.
Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in Pennsylvania as a new customer utilizing Positron’s Attrius® PET System and services. Positron will install the Attrius in the coming months concurrent with the facility’s radiopharmaceutical timeline.

Positron is the only company in the industry offering a dedicated PET scanner optimized for nuclear cardiology. The Attrius is a 2D quantitative PET scanner that provides robust high-resolution images that complements coronary flow reserve software to produce accurate measurements of absolute blood flow.

Positron’s new Attrius customer will take advantage of the Company’s Lease to Own & Services Program which provides  a complete package of Attrius PET System and the full scope Clinical & Technical Services for one monthly price for five years. Positron’s Lease to Own Program has zero upfront capex expense and provides the most viable operational model for nuclear imaging practices seeking the PET modality. Positron is working with several parties interested in its Attrius dedicated PET and expects to enter additional lease to own/services agreements upon customers completion of site preparation and  radiopharmaceutical supply agreements.

Adel Abdullah, President of Positron stated, “We are pleased to be part of our customers evolution from SPECT to cardiac PET imaging. Our Attrius PET is a tremendous tool for advanced cardiac studies and diagnostics, and we are excited for our customers to take full advantage of the capabilities of our Attrius PET, services, training, and innovative new lease to own program. Our objectives are fully in-line with our physicians and practices in providing  the best quality medical care,  which we achieve through Positron’s PET technology and equally important clinical services and all at a favorable price point. Our clinical team provides expert training and assistance necessary to assure that our customers receive the full benefits of the Attrius PET system and quantification software. Positron’s Attrius dedicated PET system and services provides nuclear imaging practices the best value through the combination of high technology and  cost-effective imaging solutions.

The future of nuclear imaging is in the PET modality. We look forward to playing our part by providing hospitals and private practices with the best technology, services, and solutions to fully meet our customers’ needs,” concluded Mr. Abdullah.

About Positron Corporation

Positron Corporation is a molecular imaging device company that offers a state-of-the-art PET imaging system and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET technology, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.


Positron's dedicated PET system, Attrius® PET, and unique market position are substantial advantages in facilitating the adoption of cardiac PET and the growth of the nuclear imaging market.

Positron will soon offer a state-of-the-art PET-CT molecular imaging device that will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT also allows the Company to fully service and meet the demands of the vast oncology diagnostics marketplace.  Positron will continue to advance the technology through its manufacturing and R&D venture with Shenyang Intelligent Neuclear Medical Technology Co. Ltd., a wholly owned subsidiary of Neusoft Medical Systems.

Forward-Looking Statements

This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com or contact: investor@positron.com

Incredible news. Positron will complete the 510K FDA approval in the next 60 days. As I have stated before a company on a $30mio market capitalization, partners with Neusoft Medical and Ochsner Clinic/Dr. Bober is completely undervalued. We can only expect good things in the furfure.
Positron Corporation Enters into Agreement with Ochsner Clinic Foundation for Clinical Study of its New “Affinity PET-CT 4D” Device
Press Release | 03/01/2023
Niagara Falls, NY, March 01, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a molecular imaging device company that offers PET imaging systems and clinical services, is pleased to announce that it has executed a Clinical Study/Research Agreement with Ochsner Clinic Foundation and Dr. Bober, Director of Molecular Imaging and Nuclear Cardiology at Ochsner Health, for the clinical study of its new PET-CT imaging device, the Affinity™ PET-CT 4D.

All procedures and participants for the clinical study have been evaluated and approved as required by an independent Institutional Review Board (IRB). Under FDA regulations, an IRB is an appropriately constituted group formally designated to review and monitor biomedical research involving human subjects.

Acceptance of the clinical study by the IRB allows Positron to obtain an Investigational Device Exemption (IDE) which is required to collect safety and efficacy data for Positron’s new PET-CT device. The clinical study will be registered in accordance with the requirements of the International Committee of Medical Journal Editors. Clinical studies are most often conducted to support a PMA (Pre-Market Approval) as required in the submission of a 510k with the FDA.

Positron has met all criteria to immediately begin the installation process and phantom testing in preparation for patient scans that will begin upon receiving an IDE as required for human studies. During the clinical trial period, the Company will also submit its new device 510k to the FDA. Positron expects completion of its clinical study and FDA Certification within the next 60 days.

Adel Abdullah, President of Positron, stated, “This study is key in the commercialization of the Affinity PET-CT 4D and we are very pleased to be working with such esteemed industry leaders in Ochsner Clinic Foundation and Dr. Bober. We are conducting this rigorous clinical study for the validation of our Affinity PET-CT 4D’s to demonstrate its superior capabilities and robust utilization across cardiology and oncology segments of nuclear molecular imaging. We look forward to meeting the demands of an expanding nuclear imaging device market with our Affinity PET-CT 4D providing an optimal solution.”

About Positron Corporation

Positron Corporation is a molecular imaging device company that offers a state-of-the-art PET imaging system and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging - the gold standard in cardiac diagnostics. Positron’s innovative PET technology, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.

Positron's dedicated PET system, Attrius® PET, and unique market position are substantial advantages in facilitating the adoption of cardiac PET and the growth of the nuclear imaging market.

Positron will soon offer a state-of-the-art PET-CT molecular imaging device that will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT also allows the Company to fully service and meet the demands of the vast oncology diagnostics marketplace. Positron will continue to advance the technology through its manufacturing and R&D venture with Neusoft Medical Systems.

posc

Lantheus F18 studies look great.
Expectations should be raised 10x.
Transforming cardiac PET MPI.
Very impressive.

Approval of Flurpiridaz to be announced in September. Unit dose make PET undisputed best approach of cardiac imaging.

This is huge news. Game changer for this company without question. Let’s go.

$POSC Positron Corporation Announces Key Sales & Services Personnel Hire Press Release | 06/24/2022

Niagara Falls, NY, June 24, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce that Christopher Reilly has joined Positron to lead the Company’s PET-CT Services and Systems Sales. Through a career spanning over three decades, Mr. Reilly has acquired vast expertise and industry knowledge in all aspects of SPECT imaging systems, services, pharmaceuticals and practice workflows. Mr. Reilly’s focus will be working with the many hospitals and cardiology practices that are seeking to transition from SPECT to PET imaging as their primary modality for nuclear cardiac studies and advanced diagnostics.

During the next three months, the Company along with an industry leading healthcare organization and physician, will be validating Positron’s new PET-CT device. Christopher Reilly joining Positron comes at an optimal time with the start of this validation, as his background of working directly with nuclear imaging practices will be a tremendous asset during this process.

Adel Abdullah, President of Positron, stated: “Chris brings substantial value to Positron’s expansion objectives, and we are confident he will open many opportunities to service the nuclear imaging community he knows so well. Chris is a seasoned professional who comes to us with an incredible amount of knowledge of the nuclear imaging industry in both SPECT and PET modalities; the addition of Chris is an important next step in our sales and marketing initiatives as we prepare to launch our new PET-CT product later this year. We are excited to begin our work to meet the increasing demand for PET imaging which is being driven by a migration from SPECT to PET imaging as the preferred first line nuclear cardiac study.”

About Positron Corporation

About Positron: Positron Corporation is a nuclear medicine PET imaging device company specializing in the field of cardiac Positron Emission Tomography imaging - the gold standard in cardiac diagnostics. Positron’s innovative PET technology, clinical services and practice solutions enables healthcare providers to more accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine. Positron's PET only system, market position and approach in facilitating the adoption of cardiac PET are substantial advantages to the growth of the market and Positron. Positron will soon offer a state-of-the-art PET/CT imaging device that will enable nuclear cardiologists to utilize the full power of nuclear imaging. This same PET/CT device allows Positron to address and meet the needs and demand of the vast oncology diagnostics marketplace.

Forward-Looking Statements

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact:


Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Lisa Gray, Senior Account Manager
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: (646) 893-5835
Email: lisa@skylineccg.com

New Website, yes it looks great and updated to what is going on with the company.
What is really interesting is the content within, it basically is the roadmap of where the company will be concentrating it's efforts by entering the highly lucrative PET/CT marketplace. The company with there partner Neusoft Medical will be manufacturing and selling state of the art, 4D medical scanners at prices significantly less than the competition, The current market capitalization of this company is silly at $25mio. If the company sells 5 machines at an average of $2mio plus service revenues of $250k annually, it's in my opinion it should be at least 4x, yet I'm in the camp that Positron will sell at a minimum 20+ annually, therefore the stock is now trading at a very serious discount. I have been accumulating weekly it's a slow arduous task but I'm getting a position and that's all that matters. Hopefully, before all the news starts flying I can get fully positioned. The risk/reward is perfect at these levels. Positron has survived 40+ years with PET only. Now it's similar to a Phoenix from the flames with PET/CT. Looking forward to the future and a higher multiple of stock price.

Positron.com check it out if you haven't

This thing can go on a run quick with the low O/S. The tech is their, now they need to get the word out. I smell $5.00 range

Website looks terrific. Glad to see some of the preparations for launch coming to life.
Onward and upward.

Sometimes, I feel like I'm messaging myself but ,maybe there are interested parties who like me believe this stock will be making me serious money in the short term and for sure in the long term. There has been some serious accumulation of size down around the $0.70 price. I'm expecting something really big to be on the horizon. No way this stock should be at this level. Positron had a game changer of a news release in which they will be selling a state of the art 4D PET/CT for a price that is 50% less expensive than all the competitors. Positron will be the WalMart of medical scanners. You have reimbursement at record levels, aged machines, aging population and a massive SPECT issue, plus Coronary flow the absolute wild card.
All this and the company trades at a $25mio mkt capitalization. This should be in my honest opinion at least a $250mio mkt. cap. which gives me a $7.00 per share. I would expect an announcement from mgmt. that they have initiated a stock buyback. That might wake up the world to what Positron is on the verge. Change does not happen over night in the case of Positron it too a mere 40 years to be in a position of greatness.

All quiet on the boards and in the security. Fortunately, for all of us trying to buy some stock before the FDA approval there seems to be a seller around $1.20. It must be someone who does not read the news that is dwindling out of the company. The transaction with Neusoft Medical is a game changer, multi-billion company dealing with currently a small company like Positron should make investors step back and wonder Why?. As the proverb states where there is smoke there must be Fire. Positron seems to have total control of the partnership, as they will hold the FDA approval and exclusive rights to the North American market. We shall see how many Doctors will switch from SPECT to PET/CT, as SPECT will be extremely difficult with the lack of radioisotopes, so the best solution will be the State of the Art 4D Positron system in terms of pricing points and imaging.
If anyone is out there looking for some exchange of ideas, please let's begin......

Next Steps
I believe the next steps for Positron to make going forward is the FDA submission of the new PET/CT machine. This will show the investment community that the company is moving forward in a timely manner. The FDA approval process should be somewhat quick as it's a machine and not a new trial of a drug which could take years. In general Medical devices seeking approval is at best a few months.
The 510K submission is just a submission for approval, if the company can complete the process in the next few months, I would believe that could relate for the company to have sales in calendar year 2022. This of course will propel the share price upwards to reflect a proper market capitalization for medical devices. It will be an interesting next few months, the positive is that the downside is limited and only the amount of upside is the unknown.

Flurpiridaz F-18 is going to make cardiac PET MPI much more accessible to small and medium cardiology practices currently using SPECT for MPI.

Digirad, the largest dedicated cardiac SPECT manufacturer's blog provides the most succinct description of why Fluorpiridaz is going to create a sea change from SPECT to PET for non-invasive cardiac imaging:
https://www.digirad.com/flurpiridaz-change-cardiac-pet-imaging/

When the incumbent provides that rosy of an outlook for the coming disruption, you have to respect their intellectual honesty and the said advantages the new technology will bring!

The trial completion is expected in April 2022:
https://clinicaltrials.gov/ct2/show/NCT03354273

WVU indicates the trial enrollment is closed, so it seems to be on schedule:
https://wvumedicine.org/heart/clinical-research/clinical-trials/

Apples, That is an impressive hold.
I definitely agree with you on the future price action. The announcement is what got my interest, the I did some research into this 30 year old company with it's High's and Low's.
This announcement for me, is the creation of an entirely new company. The ability to compete with a PET/CT against the large players with a new state of the state of the Art tech. offering 4D scans is value alone. If the company executes it's sales, it will have a serious multiply and will trade much higher than today's price. The only issue is limited float, which makes it tough to own, but on the other side of the dilemma is as the price action goes higher, the company can apply to a bigger exchange and do an offering with a major firm. I paid $1.25 yesterday for 2500 shares to see if the offer was good and it stayed, so there is a seller. Let's hope they try and push it down a bit so I can get a cheaper cost average. The $8.00.
Did you ever think of dollar cost averaging? It seems the logical thing to do given your holding price.
Best of Luck.

I can see a much higher value in short time. My avg is over $8.00 a share. Been here for over a decade.

How about them Apples. Please stop telling people to hold, I have bids below the market and the stock is not playing nice for me. I need to shares and I refuse to bid up. I understand the train is leaving the station but I don't have enough yet, so I need some weak hands that hopefully don't understand what the company is doing and the upside that is surely to happen over the next few months. FDA approval is a given as it's a PET/CT system already being sold through Asia and the MENA region by Neusoft Medical. So, it a foregone conclusion that the FDA approval is imminent. This company is worth $150mil. all day long. When investors understand the opportunity at hand the price action will follow. To be continued....

$POSC going up much higher! Hold those shares tight. FDA approval coming ??

Nice Price action lately. Still holding a bunch $5 incoming.

Medtrade77, Many thanks for that focus. I think the bigger news and one of the primary reasons I'm a new investor is the following news release about the shortages of isotopes. The shortage will literally make SPECT cameras as worthless as my Peloton bicycle that now serves as a hanger for my dirty laundry. As doctors will need to find a solution quickly to the SPECT issue for scans, Positron is well positioned to gain some traction of the 20,000 SPECT cameras in the USA alone.

Water leak at Dutch reactor imperils supplies of medical isotopes
By Will Morton, AuntMinnie.com staff writer

January 26, 2022 -- A shutdown at a nuclear reactor in Petten, the Netherlands, will impact global supplies of molybdenum-99 (Mo-99) and lutetium-177 (Lu-177) for medical use in coming weeks, warned Europe's nuclear medicine agency.



Radioisotope manufacturer Nuclear Research and Consultancy Group (NRG) informed Nuclear Medicine Europe (NMEu) that it shut down its High Flux Reactor (HFR) in Petten on January 20 after detecting a water leak in the reactor beam tube cooling system. There was no risk to workers or the general public, and the reactor remains in stand-by status pending an investigation, said NMEu's Emergency Response Team.

Mo-99 and Lu-177 targets that had been scheduled to be irradiated are now delayed, and the supply of the isotopes will be impacted. Both isotopes are used for medical applications, with Mo-99 being the precursor to technetium-99m, one of the most widely used radioisotopes for nuclear cardiology. Lu-177 is often used for therapeutic applications.

"Medical institutions should contact their radioisotope suppliers to determine the specific impact on their orders," NMEu stated in the notice.

In a call with HFR officials on January 24, NMEu said it was informed that endoscopic inspections of difficult to access piping have been performed, but the root cause of the leak has not been identified. Additional inspections are foreseen this week.

The NRG project team in place will determine what kind of actions will be required to address the leak and enable the reactor to return to service after regulatory review and approval, NMEu stated.[/color]

If anyone wants more insight to the focus of nuclear cardiac imaging.
The big companies are in full expansion mode.

Lantheus

Flurpiridaz F 18 is a fluorine 18-based PET MPI agent designed to assess blood flow to the heart. On April 25, 2017, we announced entering into a definitive, exclusive Collaboration and License Agreement with GE Healthcare for the agent’s continued Phase 3 development and worldwide commercialization. The second Phase 3 trial is now underway; however, because of the COVID-19 pandemic, enrollment in the global clinical development program had been delayed and has now resumed at a slower recruiting pace. GE Healthcare now expects to complete enrollment in the second half of 2021 and, assuming regulatory approval, begin commercialization in early 2023

I happen to agree with you on the 20X multiplier also, as I stated in my message, I was being extremely prudent. I believe today's price action is also being prudent. When I see the market cap. related to what is happening at the company, it makes me wonder what would the market cap. be if this was a private placement. I'm almost certain that if Positron was a private company, they most likely could raise $20mil for 20% of the company which would be a $100mil market cap.. The company should explore going a SPAC route as there are a host of SPAC's looking for viable companies. Thanks for the stock advice unfortunately I'm in the same camp as you. I'll move my bids up and let's hope for the best.

I do know enough about imaging to comment unfortunately I’m not a got to guy in the stock market.

In my opinion if they hit 10% of any sales you stated I’m not a believer of a 1x revenue multiplier.
Medical devices are the same as traditional metrics of 20x or more on profits.
If this company achieved the sales you represent then Positron would be 10x X 10x IMO.
I need to buy some more.

Medtrade77, As you are my go to guy on this opportunity. I have another question for you. I'm currently $0.75 for 10k, $0.65 for 20k and $0.50 for 50k. I just know if I pay up, they will run for the hills. My question therefore is : What are the chances that this stock has a push down that I will be filled. I'm most likely being penny foolish. The way I see it , this company has serious upside. I believe the total scanner market is approx. $3.3B. You have the big three, that are always going to have a majority of the sales, but if the new kid of the block Positron could get 10% of the market that would give it $300mil, Plus another $30mil in service revs.. We can be extremely prudent in our assumption of 1x trailing revs. That would equal $15.00 a share, based on the share count we previously discussed. So that's a 10x from current levels. So, of course I should just pay up, therefore second question. Do you know where size can be purchased? I called the company to ask but have not heard anything back yet. I'm using a Swiss bank for my purchase so hopefully they represent properly. Many Thanks in advance.

True it does trade as a private company. If it was private we would have to invest at a market capitalization of $200 million.
This latest announcement that they have PETCT combined system is amazing.
I’m in diagnostics and know that they will be the king of the hill.
When they move across to Oncology and Neurology I cannot fathom how big this company can get.
This is mainstream in its early stages.

Medtrade , Many thanks for the response. That's a serious price target.
I noticed they have a decent amount of cash on the balance sheet. My guess is that they will need to hire additional sales people once the FDA clearance happens. IMO, the security trades like the company is private, so whether the company is on a $35mio market capitalization or lower really does not tell the true value. The company has been around for decades and has withstood the the changes in reimbursement and shortages of radioisotopes from a decade ago. It's interesting that the company is now entering the PET/CT market, to target Oncology which in my opinion is the game changer. Massive market, with reimbursement coverage. If the company gets the correct IR/PR we should see a higher value, perhaps your $15.00 price target. So, with the share count being correct that would make it a $400mil company. This year should be the make or break, clear the FDA hurdle, get a few sales of the new product, service revs for recurring income and some market participants the price action should follow.

I know this because I inquired this a ways back.
The filing is correct.
Any lower amount you see this would be shares available to trade. The large shareholders have been around forever and their shares are not represented due to not being registered.
I understand there are so few shares to trade that it’s difficult to buy a lot. My purchases have been when available I bought.
This will not matter when they are $15 dollars a share.
Given this milestone I suspect now they will tell everyone. Couldn’t be happier until 10 times higher.
Good Luck also.

Dear All, I'm doing some research so if anyone is active and is looking to assist it would be greatly appreciated. I recently purchased Positron after the news of the deal with Neusoft as I firmly believe it's a game changer for any company but especially Positron. Selling a state of the art machine and from my understanding at a discount to the competition of GE, Siemens and Phillips. My question is more about the amount of shares outstanding I'm reading conflicting reports, 14mil, 10mil and the recent filing stating 25mil. Is there a reason there is so little volume ? Even if there is 25mil outstanding the company is worth $35mil. You would believe that the security would trade.
Doesn't make sense, even in this market. My concern is that the company is getting the word out to investors. The other issue is every time I take an offer they only fill me 100 shares.
Hopefully, someone here is paying attention and we can exchange information.
Good Luck

Major game changer for Positron.
Was expected as the next step in cardio.
They should be on everyone’s radar in cardiology for camera’s.

If they expand beyond there will be no limit on this company’s price.

6yr high closing price !!! Looks like momentum building !!! Good start to 2022!! GLTA

Wow
So others catching on to this undervalued gem. Real deal here.

I love what I hear about this company.
Once we see some news on their next steps it will start to get some respect and notoriety. Let’s go.

These guys are right it will be a billion dollar company.
Positron has the keys to the kingdom.
Enjoying the view.

The tailwinds are gusting, let's hope the company can execute.

https://www.healthimaging.com/topics/molecular/cms-retires-coverage-barriers-non-oncologic-pet

Things are finally looking good here!

The longs have been waiting a long time, we should creep back to around $5.00 and then hopefully we will hear about some deals!

Great to hear of compliance.
These guys are the real deal.
Full support from industry folks and soon investors too.

Study: 18F-FES PET may help solve clinical dilemmas in breast cancer
A study found 18F-FES PET imaging may help health care providers make treatment decisions in cases with clinical dilemmas, such as when patients with breast cancer have estrogen receptor expression that varies between tumors or when biopsies cannot be safely performed, researchers reported. "18F-FES PET has the potential to visualize the ER expression of all tumors across the body and could provide helpful information regarding clinical dilemmas in breast cancer patients," said researcher Dr. Carolina Schroder.

That's a succinct summary. I would just ad that a big tailwind for cardiac PET and this company's position as the only dedicated cardiac PET maker could allow them to build a significant business here.

They were about a decade early....but the market will finally be coming to them when GE/Lantheus get Fluorpiridaz F-18 approved.

CT scanners are expensive and unnecessary for the cardiac measurements. There's over 25 million cardiology offices that would be better served to get a dedicated PET camera without the CT.

POSC 4.4m float. 11th hour to get current. Not a shell
Wide spread will keep volume away.

This will be a news catalyst stock..

Cardiac PET predicts outcomes in aortic stenosis

September 16, 2021 -- PET imaging has shown how impaired blood flow in small vessels of the heart may lead to myocardial stress and injury in patients with aortic stenosis, according to a study published online September 15 in JAMA Cardiology.

The U.S. researchers, led by senior author Dr. Marcelo Di Carli of Brigham and Women's Hospital in Boston, used cardiac PET to analyze myocardial flow reserve in patients with aortic stenosis and compared it with patients without aortic stenosis. The team found that PET may serve as an early sign for identifying which patients are at higher risk for heart failure.

"[Myocardial flow reserve] may serve as an early sensitive marker of myocardial decompensation to identify patients with [aortic stenosis] who are at high risk," the team wrote.

Aortic stenosis is the narrowing of a patient's aortic valve, which causes increased stress in the myocardium. Patients with severe cases are at risk of heart failure and have low survival rates without aortic valve replacements.

Cardiac PET can be used to assess myocardial flow reserve, a measure of the ability of the heart's small blood vessels to increase blood flow under stress. Previous studies by Di Carli and colleagues have shown that impaired myocardial flow reserve is associated with adverse left ventricular remodeling (for instance, the thickening of the heart wall) and worse clinical outcomes in patients with aortic sclerosis.

Those studies were conducted in patients mostly with aortic sclerosis and mild disease, however. In this prospective observational study, the group sought to evaluate myocardial flow reserve on cardiac PET in patients with more severe disease.

The researchers enlisted 34 individuals with moderate to severe aortic sclerosis and 34 control individuals to participate in the study. Between 2018 and 2020, the patients underwent nitrogen-13-labeled ammonia PET myocardial perfusion imaging, resting transthoracic echocardiogram, and serum biomarker collection at Brigham and Women's Hospital in Boston.

A subset of patients underwent repeated assessment six months after aortic valve replacement.

The study authors found that myocardial flow reserve was independently associated with global longitudinal strain (GLS) and left ventricle ejection fraction. Stress myocardial blood flow was associated with high-sensitive cardiac troponin T (hs-cTnT) and N-terminal pro hormone B-type natriuretic peptide, two standard clinical biomarkers for heart failure.

The combination of low-stress myocardial blood flow and high hs-cTnT was associated with higher interventricular septal thickness in diastole, relative wall thickness, and worse GLS compared with high-stress myocardial blood flow and low hs-cTnT, the researchers found.

"Myocardial flow reserve was associated with adverse myocardial characteristics and stress myocardial flow reserve was associated with markers of myocardial stress and injury," they stated.

In addition, in nine patients studied six months after valve replacement surgery, mean myocardial flow reserve improved from 1.73 to 2.11, which further suggests myocardial flow reserve may be an early sensitive marker for myocardial decompensation, Di Carli and colleagues suggested.

The authors noted limitations, namely that the study was a single-center observational study with a relatively small sample size and that many of the patients had hypertension, which can reduce myocardial blood flow.

"Future studies are needed to investigate whether [myocardial flow reserve] alone or in combination with biomarkers of myocardial wall stress and injury may identify patients who might benefit from earlier valvular intervention, especially in those with moderate [aortic stenosis] or asymptomatic severe [aortic stenosis]," they concluded.

$POSC Positron Announces Timeline for Becoming Current with its OTC Reporting & Disclosures
Press Release | 09/14/2021
Niagara Falls, NY , Sept. 14, 2021 (GLOBE NEWSWIRE) -- Positron Corp (“Positron” or the “Company”) (OTC: POSC) is pleased to announce that Positron has received full OTCIQ access for its filing and approval process with OTC Markets. The Company is in the process of posting all required information with OTC Markets for its plan to be current with OTC Pink Markets. This process should remove the “stop” sign associated with POSC’s OTC ticker symbol. Furthermore, getting current should also mean that Positron’s shares will not be negatively impacted by the SEC’s changes to Rule 15c2-11, changes which are expected to prohibit market professionals from market making and quoting other Pink Sheet stocks that will not be current with their respective reporting.

Adel Abdullah, President of Positron stated: "The Company is currently in process of returning to a fully reporting publicly traded security. Positron has retained Rosenberg Rich Baker Berman, P.A., a PCAOB registered audit firm to perform its audit which is necessary to complete its SEC Form 10 filing. The Company expects to file its Form 10/audited financials as soon as possible.”

“Positron’s plans thereafter will be to upgrade to the OTCQB or OTCQX or up-list to a senior exchange such as Nasdaq as soon as practicable. We will update as the Company advances our relisting as well as provide information on our business progress at the end of Q3, concluded Mr. Abdullah.”

About Positron Corporation

About Positron: Positron Corporation is a nuclear medicine PET Imaging company specializing in the field of cardiac Positron Emission Tomography imaging - the gold standard in cardiac diagnostics. Positron’s innovative PET technology, clinical services and practice solutions enables healthcare providers to more accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine. Positron's PET only system, market position and approach in facilitating the adoption of cardiac PET are substantial advantages to the growth of the market and Positron.

About Skyline Corporate Communications Group, LLC

Skyline Corporate Communications Group, LLC provides strategic investor relations and corporate communications advisory services to public and late stage private companies globally. Our team has worked with more than 100 U.S. listed public companies from around the globe across diverse industries and various market caps. We have experience with shareholder activism and crisis communications, and also work with late stage private companies to help prepare them to enter the public marketplace. www.skylineccg.com

Forward-Looking Statements

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com



Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Lisa Gray, Senior Account Manager
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: (646) 893-5835
Email: lisa@skylineccg.com

Yes F18 will be a major boost for expanding the universe of users. Very exciting indeed. Don’t underestimate this short half life and pharmacologic stress, as they are attributes most practitioners value highly. Digirad insight is SPECT based in nature which they see PET as the threat on the horizon.

Yes they need to begin making some sales, but the tailwinds haven't even begun yet.

The market for dedicated cardiac PET systems for small and medium cardiology offices won't really open up until F-18 Flurpiridaz gets FDA approval. Flurpiridaz will be able to be bought in individual doses, as opposed to needing to make the significant investment in a Rb-82 generator, where schedules need to be stacked to optimize the per unit dose economics.

There's also the fact that Fluorpiridaz has a long enough half life to have patients perform exercise stress, which most cardiologists prefer over pharmaceutical stress for patients capable of running on the treadmill.

"Treadmill exercise is the preferred mode of stress in patients undergoing radionuclide MPI studies, given the increased clinical information provided by exercise testing variables. An important attribute of flurpiridaz is that it can easily be used in conjunction with exercise treadmill testing, owing to its longer (110 min) half-life of 18F. Although treadmill exercise PET-MPI is feasible using N-13 ammonia, it is not practical and commonly used (26). Exercise rubidium-82 (Rb-82) studies are not performed because of its very short half-life (75 ms). Being able to perform exercise stress has been a distinct advantage of SPECT-MPI over Rb-82 PET. Importantly, in the subset of 228 patients undergoing exercise treadmill testing in this trial, flurpiridaz PET-MPI was statistically superior to SPECT-MPI with respect to sensitivity and overall diagnostic performance as measured by area under the ROC curve."
https://www.sciencedirect.com/science/article/pii/S0735109720355315

The last timeline I heard Lantheus discus the timeline for Flurpiridaz approval was in their second quarter 2020 CC, saying GE expected to complete enrollment in mid-2021, with commercialisation in early 2023.
https://www.fool.com/earnings/call-transcripts/2020/07/30/lantheus-holdings-inc-lnth-q2-2020-earnings-call-t.aspx

But don't take my word for it, look at what the largest dedicated SPECT maker has to say about it:
https://www.digirad.com/flurpiridaz-change-cardiac-pet-imaging/

Hopefully Positron can pick up some key talent from Digirad's cardiology sales and marketing team as they build theirs.

Wow, just as stated.
Without question we can expect great things with Positron Corp.

Correct understanding the facts are important. Their public relations team stated they have OTC approval which is exactly what the company represents. I hear this is quite a process and look forward to once it’s completed.

Well you seem to know more then me on this one, Abdullah said in his message that he intends to get his paperwork up to date but who knows? I presume the OTC approval isnt axiomatic due to the very low bid and low volume. A bigger step forward would be sales and declared profits accompanied by a rights issue to allow for expansion.

I’m told until they get their financials posted on OTC the firms limit purchases.
Positron said they have complied and are waiting OTC to accept their full listing.

I understand this is in process so our journey to +100 mil in value will begin at any moment.


I see their success it’s theirs to lose.

How many are you trying to buy?

Based around previous performance lots around the 1 dollar mark.

As for 5-20 USD that seems to be pie in the sky unless the company ACTUALLY does something to justify 70 MILLION - 280 MILLION cap

As for the 100% spread, I agree the market is an absolute joke in these things.

So difficult to buy shares. I don’t believe us longs can get enough shares at these levels. Unfortunately I have to pay up.
It will go to $5.00 it may be $20.

Yes no body doubts that PET is better the SPECT in many regards, but for whatever reason, they're not selling these machines at the moment. If they were we would know about it because it would be announced. Also the return to proper accounts or paperwork seems to have been delayed for some reason, not withstanding that it was flagged by Abdullah. Until we get news on this issues all the huff puff of skyline and the investment adviser isnt going to make much difference. Bottom line they have a lot to prove.

Yes no body doubts that PET is better the SPECT in many regards, but for whatever reason, they're not selling these machines at the moment. If they were we would no about it because it would be announced. Also the return to proper accounts or paperwork seems to have been delayed for some reason, not withstanding that it was flagged by Abdullah. Until we get news on this issues all the huff puff of skyline and the investment adviser isnt going to make much difference. Bottom line they have a lot to prove.